PMV Pharma appoints Kirsten Flowers to Board; Dr. Peter Thompson resigns

PMV Pharmaceuticals, Inc.

Dr. Peter Thompson resigned from the board and committees effective January 5, 2022; not related to any disagreement.
Kirsten Flowers appointed Class I director effective January 5, 2022, filling the vacancy until the 2024 annual meeting.
Ms. Flowers is Chief Commercial Officer of Kura Oncology, with prior roles at Array Biopharma and Pfizer.
Her compensation follows the Company's Outside Director Compensation Policy; an indemnification agreement was executed.
No arrangements or family relationships exist between Ms. Flowers and any other director or officer.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Thompson

Director

PMVP · PMV Pharmaceuticals, Inc.

Effective: 2022-01-05
Successor: Kirsten Flowers
Filed: January 6, 2022, 6:59 PM ET

On January 5, 2022, Peter Thompson, M.D. notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effected on January 5, 2022.

Appointed

Kirsten Flowers

Director

PMVP · PMV Pharmaceuticals, Inc.

Effective: 2022-01-05
Filed: January 6, 2022, 6:59 PM ET

On January 5, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Kirsten Flowers as a director and Class I director of the Company to fill the vacancy of Dr. Thompson’s seat on the Board of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Thompson resigned as Director at PMV Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 5, 2022, Peter Thompson, M.D. notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effected on January 5, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kirsten Flowers was appointed as Director at PMV Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 5, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Kirsten Flowers as a director and Class I director of the Company to fill the vacancy of Dr. Thompson’s seat on the Board of the Company.

View on SEC.gov

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-003158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.